• Mathias B Forrester.
• Epidemiology and Disease Surveillance Unit, Department of State Health Services, Austin, Texas.
• J Emerg Med. 2016 Oct 1; 51 (4): 389-393.

BackgroundXylazine is a sedative, analgesic, anesthetic, and central muscle relaxant approved for animals but not humans. Although xylazine is an emerging drug of abuse, there are limited data on potentially adverse exposures to the drug.ObjectivesThe intent of this study was to describe potentially adverse xylazine exposures reported to a large poison center system.MethodsAll xylazine exposures reported to Texas poison centers between 2000 and 2014 were included. The distribution of cases by select variables was determined.ResultsOf 76 total cases, 93% of the patients were ≥20 years of age, and 54% were male. Fifty-one percent of the exposures occurred by injection, 28% by ingestion, 16% were dermal, 14% were ocular, and 3% by inhalation. Sixty-four percent of the exposures were unintentional, 32% were intentional, and 1% each was related to malicious use and adverse reaction. Sixty-seven percent of the patients were already at or en route to a health care facility when the poison center was contacted, 21% were managed on-site, and 9% were referred to a health care facility. The most common clinical effects were drowsiness or lethargy (47%), bradycardia (20%), hypotension (11%), hypertension (9%), puncture or wound (8%), and slurred speech (8%).ConclusionXylazine exposures tended to involve patients who were adult males, exposures were typically unintentional; and most often occurred by injection. Most of the patients were already at or en route to a health care facility when a poison center was contacted. The most frequently reported adverse effects were cardiovascular or neurologic in nature.Copyright © 2016 Elsevier Inc. All rights reserved.

28 keywords...

hide…